47 related articles for article (PubMed ID: 29405608)
1. Role of prophylactic azithromycin to reduce airway inflammation and mortality in a RSV mouse infection model.
Mosquera RA; De Jesus-Rojas W; Stark JM; Yadav A; Jon CK; Atkins CL; Samuels CL; Gonzales TR; McBeth KE; Hashmi SS; Garolalo R; Colasurdo GN
Pediatr Pulmonol; 2018 May; 53(5):567-574. PubMed ID: 29405608
[TBL] [Abstract][Full Text] [Related]
2. Montelukast during primary infection prevents airway hyperresponsiveness and inflammation after reinfection with respiratory syncytial virus.
Han J; Jia Y; Takeda K; Shiraishi Y; Okamoto M; Dakhama A; Gelfand EW
Am J Respir Crit Care Med; 2010 Aug; 182(4):455-63. PubMed ID: 20442434
[TBL] [Abstract][Full Text] [Related]
3. Titanium dioxide nanoparticles exaggerate respiratory syncytial virus-induced airway epithelial barrier dysfunction.
Smallcombe CC; Harford TJ; Linfield DT; Lechuga S; Bokun V; Piedimonte G; Rezaee F
Am J Physiol Lung Cell Mol Physiol; 2020 Sep; 319(3):L481-L496. PubMed ID: 32640839
[TBL] [Abstract][Full Text] [Related]
4. Polysaccharides from Platycodonis Radix ameliorated respiratory syncytial virus-induced epithelial cell apoptosis and inflammation through activation of miR-181a-mediated Hippo and SIRT1 pathways.
Li JJ; Liu ML; Lv JN; Chen RL; Ding K; He JQ
Int Immunopharmacol; 2022 Mar; 104():108510. PubMed ID: 34999393
[TBL] [Abstract][Full Text] [Related]
5. Increased Lung Catalase Activity Confers Protection Against Experimental RSV Infection.
Ansar M; Ivanciuc T; Garofalo RP; Casola A
Sci Rep; 2020 Feb; 10(1):3653. PubMed ID: 32107411
[TBL] [Abstract][Full Text] [Related]
6. Agents that increase AAM differentiation blunt RSV-mediated lung pathology.
Shirey KA; Lai W; Pletneva LM; Finkelman FD; Feola DJ; Blanco JC; Vogel SN
J Leukoc Biol; 2014 Dec; 96(6):951-5. PubMed ID: 25009233
[TBL] [Abstract][Full Text] [Related]
7. Micro-CT Features of Lung Consolidation, Collagen Deposition and Inflammation in Experimental RSV Infection Are Aggravated in the Absence of Nrf2.
Ivanciuc T; Patrikeev I; Qu Y; Motamedi M; Jones-Hall Y; Casola A; Garofalo RP
Viruses; 2023 May; 15(5):. PubMed ID: 37243277
[TBL] [Abstract][Full Text] [Related]
8.
Lau C; Behlen JC; Myers A; Li Y; Zhao J; Harvey N; Wright G; Hoffmann AR; Zhang R; Johnson NM
Environ Sci Technol; 2022 Aug; 56(16):11527-11535. PubMed ID: 35926851
[TBL] [Abstract][Full Text] [Related]
9. Role of azithromycin in antiviral treatment: enhancement of interferon-dependent antiviral pathways and mitigation of inflammation may rely on inhibition of the MAPK cascade?
Mohanta TK; Arina P; Sharma N; Defilippi P
Am J Transl Res; 2020; 12(12):7702-7708. PubMed ID: 33437355
[TBL] [Abstract][Full Text] [Related]
10. Neutrophils do not impact viral load or the peak of disease severity during RSV infection.
Kirsebom F; Michalaki C; Agueda-Oyarzabal M; Johansson C
Sci Rep; 2020 Jan; 10(1):1110. PubMed ID: 31980667
[TBL] [Abstract][Full Text] [Related]
11. Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process.
Tran DH; Sugamata R; Hirose T; Suzuki S; Noguchi Y; Sugawara A; Ito F; Yamamoto T; Kawachi S; Akagawa KS; Ōmura S; Sunazuka T; Ito N; Mimaki M; Suzuki K
J Antibiot (Tokyo); 2019 Oct; 72(10):759-768. PubMed ID: 31300721
[TBL] [Abstract][Full Text] [Related]
12. Spiramycin and azithromycin, safe for administration to children, exert antiviral activity against enterovirus A71 in vitro and in vivo.
Zeng S; Meng X; Huang Q; Lei N; Zeng L; Jiang X; Guo X
Int J Antimicrob Agents; 2019 Apr; 53(4):362-369. PubMed ID: 30599241
[TBL] [Abstract][Full Text] [Related]
13. Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols.
Elekhnawy E; Negm WA; El-Sherbeni SA; Zayed A
Inflammopharmacology; 2022 Dec; 30(6):1935-1954. PubMed ID: 36018432
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of oseltamivir in the treatment of patients infected with Covid-19.
Zendehdel A; Bidkhori M; Ansari M; Jamalimoghaddamsiyahkali S; Asoodeh A
Ann Med Surg (Lond); 2022 May; 77():103679. PubMed ID: 35531426
[TBL] [Abstract][Full Text] [Related]
15. Integrating the Human and Animal Sides of Mycoplasmas Resistance to Antimicrobials.
Pereyre S; Tardy F
Antibiotics (Basel); 2021 Oct; 10(10):. PubMed ID: 34680797
[TBL] [Abstract][Full Text] [Related]
16. Antibiotics as immunomodulators: a potential pharmacologic approach for ARDS treatment.
Sauer A; Peukert K; Putensen C; Bode C
Eur Respir Rev; 2021 Dec; 30(162):. PubMed ID: 34615700
[TBL] [Abstract][Full Text] [Related]
17. The Age, Sex, and Geographical Distribution of Self-Reported Asthma Triggers on Children With Asthma in China.
Zhang C; Kong Y; Shen K
Front Pediatr; 2021; 9():689024. PubMed ID: 34540763
[No Abstract] [Full Text] [Related]
18. Potential drug development and therapeutic approaches for clinical intervention in COVID-19.
Dowarah J; Marak BN; Yadav UCS; Singh VP
Bioorg Chem; 2021 Sep; 114():105016. PubMed ID: 34144277
[TBL] [Abstract][Full Text] [Related]
19. Antihistamines and azithromycin as a treatment for COVID-19 on primary health care - A retrospective observational study in elderly patients.
Morán Blanco JI; Alvarenga Bonilla JA; Homma S; Suzuki K; Fremont-Smith P; Villar Gómez de Las Heras K
Pulm Pharmacol Ther; 2021 Apr; 67():101989. PubMed ID: 33465426
[TBL] [Abstract][Full Text] [Related]
20. Interferon-inducer antivirals: Potential candidates to combat COVID-19.
Bagheri A; Moezzi SMI; Mosaddeghi P; Nadimi Parashkouhi S; Fazel Hoseini SM; Badakhshan F; Negahdaripour M
Int Immunopharmacol; 2021 Feb; 91():107245. PubMed ID: 33348292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
